Tom Powles: Renal cancer highlights ESMO23

Tom Powles Director of Barts Cancer Centre, shared a post on LinkedIn, saying:

“Renal cancer highlights ESMO23: R3 for Belzuifan vs everolimus: 25%  in PFS in pretreated M1. RR look good but OS not there yet. RR also look  for belzutifan/cabo (70% 1st line). A new 1st line combo: axi + toliparimab (PD-1) which look like axi/pembro PFS/OS ~0.65 RRs~60%”

Source: Tom Powles/Twitter